Lab
Iowa Physicians Clinic Medical Foundation
Iowa Physicians Clinic Medical Foundation was paid $987K by Medicaid between Jan 2018 and Dec 2024, across 79 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 9.1% of everything it billed.
33Billing provider infoIOWA PHYSICIANS CLINIC MEDICAL FOUNDATION
CEDAR FALLS, IA 50613
CEDAR FALLS, IA 50613
33aNPI1538617840assigned 09/15/2016
33bProvider typeClinical Medical Laboratory
28Total paid$987K
24GClaims93,224
24DCodes billed79
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Iowa
Rank by total paid#10 of 35
Median peer was paid$42K
This provider vs. median24×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WILLIAMS, DAVID controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,673 | $133K | |
| 2019 | 13,441 | $160K | |
| 2020 | 12,501 | $145K | |
| 2021 | 16,869 | $176K | |
| 2022 | 19,606 | $211K | |
| 2023 | 13,520 | $125K | |
| 2024incomplete | 5,614 | $37K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 9.1% | 23,494 | 21,829 | $90K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 7.5% | 2,339 | 2,145 | $74K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 7.5% | 2,339 | 2,143 | $74K |
| 84443 | Thyroid stimulating hormone (TSH) | 7.5% | 5,148 | 4,907 | $74K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 5.3% | 2,088 | 2,014 | $52K |
| 80061 | Lipid panel | 4.3% | 3,699 | 3,564 | $42K |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.6% | 4,955 | 4,722 | $36K |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.5% | 4,343 | 4,200 | $35K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.3% | 4,774 | 4,577 | $32K |
| 87660 | 2.9% | 1,521 | 1,461 | $28K | |
| 87510 | 2.9% | 1,519 | 1,460 | $28K | |
| 87480 | 2.9% | 1,519 | 1,460 | $28K |
67 more codes
| 80050 | General health panel | 2.8% | 683 | $28K |
| 80053 | Comprehensive metabolic panel | 2.7% | 2,948 | $27K |
| 85027 | 2.7% | 4,526 | $26K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.7% | 211 | $26K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.4% | 637 | $23K |
| 84439 | 2.3% | 2,997 | $23K | |
| 83655 | 2.2% | 1,821 | $21K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.0% | 156 | $20K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.9% | 1,103 | $19K |
| 84480 | 1.4% | 1,154 | $14K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.3% | 313 | $13K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.1% | 1,681 | $11K |
| 84403 | <1% | 412 | $10K | |
| 82728 | <1% | 807 | $9K | |
| 84702 | <1% | 720 | $8K | |
| 80076 | <1% | 984 | $7K | |
| 82746 | <1% | 542 | $6K | |
| 81002 | <1% | 2,106 | $6K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 15 | $6K |
| 0240U | <1% | 44 | $5K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 74 | $5K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 200 | $5K |
| 83550 | <1% | 720 | $5K | |
| 85018 | <1% | 2,011 | $5K | |
| 83540 | <1% | 830 | $5K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 35 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 45 | $4K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 245 | $3K |
| 82570 | <1% | 813 | $3K | |
| 82043 | <1% | 684 | $3K | |
| 80306 | <1% | 212 | $3K | |
| 85651 | <1% | 849 | $3K | |
| 82607 | <1% | 255 | $3K | |
| 81025 | <1% | 361 | $3K | |
| 80305 | <1% | 279 | $3K | |
| 86780 | <1% | 206 | $2K | |
| 86140 | <1% | 469 | $2K | |
| 86762 | <1% | 191 | $2K | |
| 87340 | <1% | 312 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 75 | $2K |
| 81001 | <1% | 603 | $2K | |
| 86756 | <1% | 100 | $2K | |
| 82677 | <1% | 86 | $2K | |
| 87653 | <1% | 47 | $1K | |
| 86592 | <1% | 403 | $1K | |
| 82105 | <1% | 99 | $1K | |
| 86336 | <1% | 86 | $975.44 | |
| 82950 | <1% | 217 | $877.71 | |
| 80074 | <1% | 12 | $543.00 | |
| 87581 | <1% | 15 | $499.88 | |
| 87486 | <1% | 15 | $499.88 | |
| 84163 | <1% | 33 | $399.66 | |
| 84460 | <1% | 88 | $364.35 | |
| 87070 | <1% | 38 | $357.02 | |
| 84450 | <1% | 87 | $350.75 | |
| 87186 | <1% | 15 | $155.52 | |
| 86803 | <1% | 14 | $149.16 | |
| 81003 | <1% | 76 | $141.58 | |
| 87077 | <1% | 15 | $132.70 | |
| 87081 | <1% | 14 | $106.96 | |
| 83690 | <1% | 13 | $77.31 | |
| 86431 | <1% | 12 | $59.29 | |
| 3044F | 0% | 509 | $0.00 | |
| 0064U | 0% | 45 | $0.00 | |
| 3052F | 0% | 13 | $0.00 | |
| 3051F | 0% | 56 | $0.00 | |
| 3046F | 0% | 49 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, DAVID (PRESIDENT/CEO)
Parent organizationIOWA PHYSICIANS CLINIC MEDICAL FOUNDATION
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.